Skip to main content
RankDealDateAmount ($ 000s)*
1LightSpeed POS secures Series C financing2015-07-2878,897
2Clementia Pharmaceuticals closes mezzanine financing2015-06-2273,727
3Blockstream secures Series A financing2015-10-2772,826
4Kik secures additional Series C financing2015-08-1265,500
5Resverlogix closes strategic investment and private placement2015-07-2150,383
6Cynapsus Therapeutics close public offering2015-06-2339,936
7Telesta Therapeutics closes private placement2015-08-1937,103
8Influitive completes Series B financing2015-04-2936,387
9Coveo Solutions secures Series D financing2015-11-0535,000
10Scribble Technologies closes Series D2015-09-0935,000
11Cymax Stores secures Series A financing2015-08-1433,240
12Highland Therapeutics secures new financing2015-06-2431,038
13Real Matters secures new financing2015-05-0130,000
14Breather Products closes Series B financing2015-09-1026,453
15Trillium Therapeutics closes offering2015-04-0125,364

Subscribers can see the top 50 Canadian VC deals here.

Visit The Globe's data store to purchase comprehensive tables from the Canadian Venture Capital & Private Equity Association. Tables include the top venture capital and private equity deals of 2015 and the CVCA's exclusive member list, including detailed metrics and contact information.

Story continues below advertisement

Report an error Editorial code of conduct
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

If your comment doesn't appear immediately it has been sent to a member of our moderation team for review

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.